Merck (MRK) Debt to Equity (2016 - 2025)
Merck (MRK) has disclosed Debt to Equity for 17 consecutive years, with $0.8 as the latest value for Q3 2025.
- On a quarterly basis, Debt to Equity fell 6.85% to $0.8 in Q3 2025 year-over-year; TTM through Sep 2025 was $0.8, a 6.85% decrease, with the full-year FY2024 number at $0.8, down 14.08% from a year prior.
- Debt to Equity was $0.8 for Q3 2025 at Merck, up from $0.72 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $1.16 in Q1 2021 to a low of $0.66 in Q1 2023.
- A 5-year average of $0.81 and a median of $0.8 in 2025 define the central range for Debt to Equity.
- Peak YoY movement for Debt to Equity: tumbled 32.83% in 2022, then surged 39.78% in 2023.
- Merck's Debt to Equity stood at $0.87 in 2021, then dropped by 22.99% to $0.67 in 2022, then soared by 39.78% to $0.93 in 2023, then dropped by 14.08% to $0.8 in 2024, then decreased by 0.4% to $0.8 in 2025.
- Per Business Quant, the three most recent readings for MRK's Debt to Equity are $0.8 (Q3 2025), $0.72 (Q2 2025), and $0.72 (Q1 2025).